Psychedelic Stocks

Psychedelic medicines have a long history of therapeutic potential. Now, they might be getting closer to finally becoming approved drugs.

This list is focused on the publicly traded companies advancing psychedelic drug discovery and clinical trials for psychedelic medicine.

Trend Performance

Today
-8.36
%
-8.36
%
-8.36
%
Past Week
3.66
%
3.66
%
3.66
%
Past Month
-4.44
%
-4.44
%
-4.44
%
Past 3M
36.36
%
36.36
%
36.36
%
Past 6M
28.73
%
28.73
%
28.73
%
Past Year
-6.37
%
-6.37
%
-6.37
%
Past 2 Years
102.52
%
102.52
%
102.52
%

What's Included?

Companies

CYBN

Cybin

Cybin is a biopharmaceutical leader developing innovative psychedelic-based therapeutics for mental health, including depression and anxiety disorders.
1D
-4.69
%
-4.69
%
-4.69
%
1M
-8.52
%
-8.52
%
-8.52
%
1Y
-38.64
%
-38.64
%
-38.64
%
2Y
-49.18
%
-49.18
%
-49.18
%
MNMD

MindMed

MindMed pioneers psychedelic-inspired therapies to address mental health disorders, aiming to transform treatment for anxiety, ADHD, and autism spectrum disorder.
1D
-12.82
%
-12.82
%
-12.82
%
1M
-2.95
%
-2.95
%
-2.95
%
1Y
63.28
%
63.28
%
63.28
%
2Y
165.79
%
165.79
%
165.79
%
ATAI

atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company developing innovative treatments for mental health disorders, aiming to transform patient care.
1D
-7.43
%
-7.43
%
-7.43
%
1M
1.89
%
1.89
%
1.89
%
1Y
-26.03
%
-26.03
%
-26.03
%
2Y
-7.43
%
-7.43
%
-7.43
%
CMPS

Compass Pathways

Compass Pathways pioneers evidence-based mental health innovations, developing psilocybin therapies for treatment-resistant depression and other serious conditions.
1D
-9.61
%
-9.61
%
-9.61
%
1M
-13.93
%
-13.93
%
-13.93
%
1Y
-57.71
%
-57.71
%
-57.71
%
2Y
-50.89
%
-50.89
%
-50.89
%
MIRA

MIRA Pharmaceuticals

MIRA Pharmaceuticals develops novel oral ketamine and marijuana analogs to treat neurologic and neuropsychiatric disorders.
1D
-10.74
%
-10.74
%
-10.74
%
1M
8.13
%
8.13
%
8.13
%
1Y
23.15
%
23.15
%
23.15
%
2Y
-81.00
%
-81.00
%
-81.00
%
BNOX

Bionomics

Bionomics develops novel ion channel modulators for treating serious central nervous system disorders like anxiety and PTSD.
1D
-9.80
%
-9.80
%
-9.80
%
1M
-10.61
%
-10.61
%
-10.61
%
1Y
-78.36
%
-78.36
%
-78.36
%
2Y
-92.99
%
-92.99
%
-92.99
%
MDMA

PharmAla Biotech

PharmAla Biotech is a Canadian company specializing in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds.
1D
-3.45
%
-3.45
%
-3.45
%
1M
-5.08
%
-5.08
%
-5.08
%
1Y
69.70
%
69.70
%
69.70
%
2Y
833.33
%
833.33
%
833.33
%

Crypto

No items found.

Recent Articles

All Articles

Discover the world's most disruptive early stage companies with 40,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.